GI
SPRY icon

GAMMA Investing’s ARS Pharmaceuticals SPRY Stock Holding History

GAMMA Investing’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.1K Buy
1,256
+653
+108% +$5.62K ﹤0.01% 3200
2026
Q1 		$4.84K Buy
603
+495
+458% +$4.74K ﹤0.01% 3372
2025
Q4 		$1.26K Sell
108
-71
-40% -$690 ﹤0.01% 3729
2025
Q3 		$1.8K Sell
179
-116
-39% -$1.67K ﹤0.01% 3476
2025
Q2 		$5.15K Buy
295
+28
+10% +$404 ﹤0.01% 3104
2025
Q1 		$3.36K Buy
267
+191
+251% +$2.3K ﹤0.01% 3236
2024
Q4 		$802 Sell
76
-31
-29% -$434 ﹤0.01% 3476
2024
Q3 		$1.55K Buy
107
+31
+41% +$369 ﹤0.01% 3140
2024
Q2 		$647 Sell
76
-24
-24% -$213 ﹤0.01% 3155
2024
Q1 		$1.02K Buy
100
+24
+32% +$179 ﹤0.01% 2937
2023
Q4 		$472 Buy
+76
New +$333 ﹤0.01% 2980

Other funds holding SPRY

PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
NFGCM
Norman Fields Gottscho Capital Management New York $330M AUM 27.75% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.46B AUM 21.89% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

GAMMA Investing's SPRY Position: Q2 2026 in Review

GAMMA Investing increased its ARS Pharmaceuticals (SPRY) stake by 108% in Q2 2026, buying an estimated $5.62K and bringing the position to 1,256 shares worth $10.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3200.

GAMMA Investing first reported a position in SPRY in Q4 2023 and has held it in 11 quarters since. 8 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • GAMMA Investing held 1,256 shares of ARS Pharmaceuticals worth $10.1K as of Q2 2026.
  • GAMMA Investing bought 653 ARS Pharmaceuticals shares in Q2 2026, an estimated $5.62K.
  • ARS Pharmaceuticals made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3200 holding.
  • GAMMA Investing first reported a position in ARS Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 8 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.